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Background: In acute coronary syndrome (ACS) women have higher morbidity, mortality and risk of bleeding than men, which may be partially 
explained by differences in baseline characteristics, but also by differences in response to antithrombotic therapy.
Methods: We performed a subset analysis of PLATO data to assess the effect of gender on efficacy and treatment-related complications of 
ticagrelor (T) vs. clopidogrel (C) in patients with ST-elevation or non-ST-elevation ACS. Hazard ratios and 95% confidence intervals (CI) were adjusted 
for baseline covariates, including age. Nominal significance levels were not corrected for multiplicity.
Results: Women and men had similar rates of cardiovascular death, myocardial infarction and stroke (1.00; 0.89-1.12) and total mortality (0.92; 
0.78-1.08), but women had less overall major bleeding (0.80; 0.71-0.90) because of lower use of coronary artery bypass graft (CABG) surgery. T 
consistently reduced ischemic endpoints and mortality, regardless of gender (table). There was no significant increase in overall major bleeding, and 
the increase in non-CABG related major bleeding tended to be less in women than men. Dyspnea and ventricular pauses were more frequent with T, 
and did not differ by sex. 
N T C Adjusted Hazard Ratio (95% CI) Interaction p-value
CV death, MI, or stroke
Women 5288 11.2 (276) 13.2 (327) 0.88 (0.74-1.06) 0.88
Men 13336 9.4 (583) 11.1 (685) 0.87 (0.77-0.98)
Total death
Women 5288 5.8 (143) 6.8 (167) 0.92 (0.71-1.19) 0.50
Men 13336 4.0 (254) 5.7 (338) 0.82 (0.68-0.99)
Definite stent thrombosis
Women 2689 1.2 (15) 1.4 (19) 0.74 (0.38-1.44) 0.69
Men 8600 1.4 (56) 2.1 (86) 0.63 (0.45-0.88)
Major bleeding
Women 5237 10.7 (252) 10.6 (247) 1.00 (0.82-1.22) 0.43
Men 13184 12.0 (707) 11.5 (680) 1.10 (0.98-1.24)
Non-CABG major bleed
Women 5327 6.1 (142) 5.2 (124) 1.19 (0.90-1.56) 0.42
Men 13184 3.8 (219) 3.3 (180) 1.37 (1.10-1.72)
Conclusion: In women with ACS, T reduced ischemic events and mortality compared with C without an increase in major bleeding; there were no 
significant differences in extent between men and women with ACS. T may therefore be a useful ACS treatment in women as well as in men.
